Shionogi & Co., Ltd. plans to invest USD 2.125 billion (approximately JPY 334.793 billion) to increase its voting rights ratio in ViiV Healthcare Ltd. from 10.0% to 21.7%, thereby achieving application as an equity-method affiliate (to be acquired by the end of March 2026).<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4507","jir_company_name":"Shionogi & Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-01-20","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/01\/4507-20260120-01.pdf","jir_short_summary":"Shionogi & Co., Ltd. plans to invest USD 2.125 billion (approximately JPY 334.793 billion) to increase its voting rights ratio in ViiV Healthcare Ltd. from 10.0% to 21.7%, thereby achieving application as an equity-method affiliate (to be acquired by the end of March 2026).","jir_summary":"### Background and Purpose of the Investment\nShionogi & Co., Ltd. considers \"liberation from the threat of infectious diseases\" a critical issue and focuses on HIV infection. Since 2001, it has collaborated with ViiV Healthcare Ltd. and GSK plc to successfully develop integrase inhibitors. This additional investment aims to strengthen the partnership with ViiV and contribute to global HIV treatment and prevention.\n\n### Outline of the Agreement and Future Outlook\nThe company will invest USD 2.125 billion to acquire newly issued shares of ViiV, increasing its voting rights ratio to 21.7% and applying the equity method of accounting for ViiV as an affiliate. The share acquisition is planned to be executed by the end of March 2026, with a minimal impact on consolidated results for the fiscal year ending March 2026. Profit contributions are expected from the fiscal year ending March 2027 onward.","jir_financial_highlights":"Acquisition Price: USD 2.125 billion (JPY converted: 334,793 million) (Unknown)\nVoting Rights Ratio (Before Acquisition): 10.0% (Unknown)\nVoting Rights Ratio (After Acquisition): 21.7% (Increase of 11.7 points)","jir_category":"","jir_hashtags":"#Shionogi, #M&A, #IR","jir_key_figures":"Acquisition Price: USD 2.125 billion (approximately JPY 334,793 million)\nVoting Rights Ratio: 10.0% before acquisition, 21.7% after acquisition\nScheduled Share Acquisition Completion Date: By the end of March 2026","jir_meta_title":"Shionogi Invests USD 2.125 Billion in ViiV Healthcare Ltd., Increasing Voting Rights Ratio to 21.7%","jir_meta_description":"Shionogi has made an additional investment of USD 2.125 billion in ViiV Healthcare Ltd., raising its voting rights ratio from 10.0% to 21.7%, resulting in application as an equity-method affiliate. Impact on earnings for fiscal 2026 is minimal, with profit contributions expected from fiscal 2027 onward.","jir_og_title":"Shionogi Announces Additional Investment in ViiV Healthcare Ltd.","jir_og_description":"By investing USD 2.125 billion, Shionogi increases its voting rights ratio in ViiV Healthcare Ltd. to 21.7%, planning to apply the equity method of accounting.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":6919,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"m_and_a_alliance","footnotes":""},"sector":[],"importance":[],"class_list":["post-19870","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n